Stock BIOA B BIOARCTIC AB
Add to a list
To use this feature you must be a member
Log inSign up

Company BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:37 26/04/2024 BST 		5-day change 1st Jan Change
197.5 SEK +1.96% Intraday chart for BioArctic AB +0.41% -26.25%
04-22 Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest DJ
04-15 Nordic Shares Moved Upward Monday; Invisio Led Increases DJ

Business Summary

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Number of employees: 88

Sales per Business

SEK in Million2022Weight2023Weight Delta
Innovative Biological Drugs
100.0 %
228 100.0 % 616 100.0 % +169.83%

Sales per region

SEK in Million2022Weight2023Weight Delta
Asia (Japan)
100.0 %
170 74.4 % 616 100.0 % +262.75%

Managers

Managers TitleAgeSince
Gunilla Christina Osswald CEO
 Chief Executive Officer 63 31/12/12
Pär Lars Gellerfors FOU
 Founder 77 23/01/03
Lars Gunnar Lannfelt FOU
 Founder 75 23/01/03
Anders Martin-Löf DFI
 Director of Finance/CFO 53 31/05/23
Johanna Fälting CTO
 Chief Tech/Sci/R&D Officer 52 31/12/11
Tomas Odergren CTO
 Chief Tech/Sci/R&D Officer 65 31/12/18
Christer Möller CTO
 Chief Tech/Sci/R&D Officer 65 31/12/05
Oskar Bosson IRC
 Investor Relations Contact 48 17/05/20
Anna-Kaija Grönblad PRN
 Corporate Officer/Principal 56 31/12/20
Gunilla Andersson HRO
 Human Resources Officer 63 31/12/18

Members of the board

Members of the board TitleAgeSince
Eugen Steiner CHM
 Chairman 70 31/12/16
Cecilia Marie Edström BRD
 Director/Board Member 58 31/05/23
Åke Mikael Smedeby BRD
 Director/Board Member 56 -
Charlotta Ljungqvist BRD
 Director/Board Member 63 05/05/21
Lars Gunnar Lannfelt FOU
 Founder 75 23/01/03
Pär Lars Gellerfors FOU
 Founder 77 23/01/03
Lennart Rolf Ivar Verner BRD
 Director/Board Member 77 31/12/09
Bengt Håkan Englund BRD
 Director/Board Member 72 06/05/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 14,399,996 0 0 44.12 %
Stock B 1 73,914,989 38,962,931 ( 52.71 %) 0

Shareholders

NameEquities%Valuation
Lars Gunnar Lannfelt
28.35 %
20,885,052 28.35 % 421 M kr
Pär Lars Gellerfors
18.11 %
13,343,201 18.11 % 269 M kr
Fjärde AP-fonden
6.454 %
4,753,960 6.454 % 96 M kr
Tredje AP-fonden
4.476 %
3,297,088 4.476 % 66 M kr
Swedbank Robur Fonder AB
3.695 %
2,722,073 3.695 % 55 M kr
Unionen
2.987 %
2,200,000 2.987 % 44 M kr
Nordea Investment Management AB
2.534 %
1,866,846 2.534 % 38 M kr
Investment AB Öresund (Investment Company)
1.358 %
1,000,000 1.358 % 20 M kr
Indecap Fonder AB
0.7382 %
543,771 0.7382 % 11 M kr
Storebrand Asset Management AS
0.4132 %
304,358 0.4132 % 6 M kr
NameEquities%Valuation
Lars Gunnar Lannfelt
60.00 %
8,639,998 60.00 % 174 M kr
Pär Lars Gellerfors
40.00 %
5,759,998 40.00 % 116 M kr

Company contact information

BioArctic AB

Warfvinges väg 35

112 51, Stockholm

+46 86 95 69 30

http://www.bioarctic.se
address BioArctic AB(BIOA B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for BioArctic AB

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
197.5 SEK
Average target price
366.2 SEK
Spread / Average Target
+85.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOARCTIC AB Stock BioArctic AB
-26.25% 1.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BIOA B Stock
  4. Company BioArctic AB